Trials / Unknown
UnknownNCT01011660
Effects of Angiotensin II Receptor Blocker Compared With Diuretics in High-risk Hypertensive Patients
Phase 4 Study of Effects of ARB Compared With Diuretics in Hypertension Patients With High Cardiovascular Risks
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 13,542 (estimated)
- Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital · Academic / Other
- Sex
- All
- Age
- 50 Years – 79 Years
- Healthy volunteers
- Not accepted
Summary
The aim of the study is to investigate the optimized treatment strategy of hypertension, so as to make more patients to reach the blood pressure goals and to reduce cardio-cerebrovascular events. Objective and Methods: Patients are eligible for inclusion in the study if they are essential hypertension, 50-79 years of age with at least one cardiovascular risk factor and sign the informed consent forms. This project is a multi-centre, prospective randomized,,openlabel blind-endpoint evaluation controlled (PROBE) trial. 12000 patients will be randomly assigned to either of low-dose Amlodipine+Telmisartan group or Amlodipine+ diuretics group. Among those patients with serum cholesterol between 4.0-6.1mmol/L, they will be also randomized into small dose of statin-based regimen or standard management regimen; Patients will also randomly assigned to intensive lifestyle intervention group or standard intervention group according to the community area where the patients in.
Detailed description
This study is aimed to observe the main outcome (stroke, myocardial infarction and death from cardiovascular disease) differences between different groups.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Amlodipine, Telmisartan, Amiloride Compound , Simvastatin | Amlodipine; Telmisartan; Amiloride Compound; Simvastatin |
Timeline
- Start date
- 2007-10-01
- Primary completion
- 2012-08-01
- Completion
- 2012-12-01
- First posted
- 2009-11-11
- Last updated
- 2012-08-13
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT01011660. Inclusion in this directory is not an endorsement.